Nirvana Life Sciences Inc.

OTCPK:NIRV.F Stock Report

Market Cap: US$1.7m

Nirvana Life Sciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bruce Clark

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.3yrs
CEO ownership13.2%
Management average tenureno data
Board average tenure6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bruce Clark's remuneration changed compared to Nirvana Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jan 31 2025n/an/a

-CA$544k

Oct 31 2024n/an/a

-CA$460k

Jul 31 2024n/an/a

-CA$567k

Apr 30 2024n/an/a

-CA$872k

Jan 31 2024n/an/a

-CA$1m

Oct 31 2023n/an/a

-CA$1m

Jul 31 2023n/an/a

-CA$2m

Apr 30 2023CA$180kCA$180k

-CA$1m

Jan 31 2023n/an/a

-CA$6m

Oct 31 2022n/an/a

-CA$6m

Jul 31 2022n/an/a

-CA$6m

Apr 30 2022CA$180kCA$180k

-CA$6m

Jan 31 2022n/an/a

-CA$991k

Oct 31 2021CA$180kCA$180k

-CA$959k

Apr 30 2021n/an/a

-CA$735k

Compensation vs Market: Insufficient data to establish whether Bruce's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.

CEO

Bruce Clark (62 yo)

7.3yrs

Tenure

CA$180,000

Compensation

Mr. Bruce Clark is Chief Executive Officer at Nirvana Life Sciences Inc. and serves as its Director since December 04, 2017. He is a principal of Broadwing Renewables Inc., Anyox Hydro Electric Corporation...

Board Members

NamePositionTenureCompensationOwnership
Bruce Clark
CEO & Director7.3yrsCA$180.00k13.18%
$ 221.6k
Patricia Storey
Director7.9yrsno data0.77%
$ 12.9k
Mark Marissen
Independent Director5.2yrsno datano data
Andrew Samann
Member of Advisory Board2.9yrsno datano data

6.2yrs

Average Tenure

Experienced Board: NIRV.F's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 18:28
End of Day Share Price 2025/01/30 00:00
Earnings2025/01/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nirvana Life Sciences Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.